DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18- year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. Dave Maughan, chief operations officer for DaVitaDav ...

DaVita HealthCare (DVA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a ...

It has been about a month since the last earnings report for DaVita HealthCare (DVA) . Shares have added about 13% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is DaVita HealthCare due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. DaVita Q2 Earnings & Revenues Top Es ...

DaVita (DVA) has witnessed strong momentum year to date, with its shares up 44% compared with the industry growth of 17.9%. The S&P 500 composite has risen 18.4% in the year-to-date period. DaVita, carrying a Zacks Rank #1 (Strong Buy) at present, is witnessing an upward trend in its stock price, prompted by the company's business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further. Denver, CO-headquartered DaVita, is ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...

Broad markets, although continuing to trend higher, are showing signs of increasing volatility and uncertainty. While there has been a strong rally in stocks since the sharp correction earlier in the month, there is something peculiar happening under the surface. Defensive sectors and stocks are making new highs, while the former leaders hover below. While I have long been encouraging investors join in the mega cap technology and artificial intelligence rally for the long-term, I also noted that the period ...

Wall Street has been maintaining its northbound journey in the second half of 2024 after an impressive first half. U.S. stock markets' rally, which started at the beginning of 2023 is showing no signs of declining barring some minor fluctuations. The rally is likely to gather pace over the remaining months this year as an interest rate cut in September is now almost certain. Under this circumstance, it should be prudent for investors to put money in those stocks with strong momentum. Here we are recommendin ...

Company Performance - DaVita HealthCare's shares have increased by 6.6% over the past month, reaching a new 52-week high of $151.05 [1] - The stock has gained 42.1% since the beginning of the year, outperforming the Zacks Medical sector's 8.6% and the Zacks Medical - Outpatient and Home Healthcare industry's 11.4% [1] Earnings and Revenue - DaVita HealthCare has consistently exceeded earnings estimates, reporting EPS of $2.59 against a consensus estimate of $2.47 in its last earnings report [2] - For the current fiscal year, the company is projected to achieve earnings of $9.90 per share on revenues of $12.79 billion, reflecting a 16.88% increase in EPS and a 5.38% increase in revenues [3] - The next fiscal year is expected to see earnings of $11.21 per share on $13.33 billion in revenues, indicating year-over-year changes of 13.22% and 4.21%, respectively [3] Valuation Metrics - DaVita HealthCare has a Value Score of A, with Growth and Momentum Scores of B, resulting in a combined VGM Score of A [6] - The stock trades at 15X current fiscal year EPS estimates, below the peer industry average of 24.1X, and at 8.9X trailing cash flow compared to the peer group's average of 13.4X [7] - The PEG ratio stands at 0.86, suggesting the company is not in the top tier from a value perspective [7] Zacks Rank - DaVita HealthCare holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [8] - The company meets the criteria for selection based on Zacks Rank and Style Scores, indicating potential for further share price appreciation [9] Industry Comparison - The Medical - Outpatient and Home Healthcare industry is performing well, with DaVita HealthCare and peers like The Pennant Group, Inc. showing strong fundamentals [12] - The Pennant Group, Inc. has a Zacks Rank of 2 (Buy) and is expected to post earnings of $0.89 per share on revenues of $673.39 million for the current fiscal year [11]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1][2]. Company Overview: DaVita HealthCare (DVA) - DaVita HealthCare currently holds a Momentum Style Score of B, indicating a favorable momentum outlook [3]. - The company has a Zacks Rank of 1 (Strong Buy), suggesting strong potential for outperformance in the market [4]. Performance Metrics - Over the past week, DVA shares increased by 0.56%, while the Zacks Medical - Outpatient and Home Healthcare industry declined by 3.11% [6]. - In the last month, DVA's price change was 5.9%, significantly outperforming the industry's 0.16% [6]. - DVA shares have risen by 5.16% over the past quarter and 38.63% over the last year, compared to the S&P 500's increases of 4.41% and 23.25%, respectively [7]. Trading Volume - The average 20-day trading volume for DVA is 698,096 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, two earnings estimates for DVA have been revised upwards, raising the consensus estimate from $9.62 to $9.90 [10]. - For the next fiscal year, two estimates have also moved higher, with no downward revisions during the same period [10]. Conclusion - Considering the positive momentum indicators and earnings outlook, DVA is positioned as a strong buy candidate for investors seeking short-term gains [10].

DENVER, Aug. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the pricing of its previously announced private offering (the "offering") of $1.0 billion aggregate principal amount of its 6.875% senior notes due 2032 (the "2032 notes"). The 2032 notes were priced at 100.000% of their face amount to yield a 6.875% coupon. The offering is expected to close on August 13, 2024, subject to satisfaction of customary closing conditions. DaVita intends to use the net proceeds from the offeri ...